Zimmer Biomet Holdings Inc (ZBH) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Zimmer Biomet Holdings Inc stock (ZBH) is currently trading at $87.64. Zimmer Biomet Holdings Inc PE ratio is 24.32. Zimmer Biomet Holdings Inc PS ratio (Price-to-Sales) is 2.08. Analyst consensus price target for ZBH is $102.33. WallStSmart rates ZBH as Hold.
- ZBH PE ratio analysis and historical PE chart
- ZBH PS ratio (Price-to-Sales) history and trend
- ZBH intrinsic value — DCF, Graham Number, EPV models
- ZBH stock price prediction 2025 2026 2027 2028 2029 2030
- ZBH fair value vs current price
- ZBH insider transactions and insider buying
- Is ZBH undervalued or overvalued?
- Zimmer Biomet Holdings Inc financial analysis — revenue, earnings, cash flow
- ZBH Piotroski F-Score and Altman Z-Score
- ZBH analyst price target and Smart Rating
Zimmer Biomet Holdings Inc
📊 No data available
Try selecting a different time range
ZBH Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Zimmer Biomet Holdings Inc (ZBH)
ZBH trades 296% above its Graham fair value of $24.14, indicating the stock may be overvalued at current levels.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Zimmer Biomet Holdings Inc (ZBH) · 10 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in market cap, peg ratio, price/book. Concerns around return on equity and eps growth. Fundamentals are solid but monitor weak areas for improvement.
Zimmer Biomet Holdings Inc (ZBH) Key Strengths (4)
Growing significantly faster than its price suggests
104.35% of shares held by major funds and institutions
Large-cap company with substantial market presence
Trading at 1.35x book value, attractively priced
Supporting Valuation Data
Zimmer Biomet Holdings Inc (ZBH) Areas to Watch (6)
Earnings declining -40.80%, profits shrinking
Low profitability relative to shareholder equity
Thin operating margins with cost pressures present
Thin profit margins with limited profitability
Revenue is fairly priced at 2.08x sales
Solid revenue growth at 10.90% per year
Zimmer Biomet Holdings Inc (ZBH) Detailed Analysis Report
Overall Assessment
This company scores 59/100 in our Smart Analysis, earning a C grade. Out of 10 metrics analyzed, 4 register as strengths (avg 9.3/10) while 6 fall into concern territory (avg 3.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on PEG Ratio, Institutional Own., Market Cap. Valuation metrics including PEG Ratio (0.60), Price/Book (1.35) suggest the stock is attractively priced.
The Bear Case
The primary concerns are EPS Growth, Return on Equity, Operating Margin. Some valuation metrics including Price/Sales (2.08) suggest expensive pricing. Growth concerns include Revenue Growth at 10.90%, EPS Growth at -40.80%, which may limit upside. Profitability pressure is visible in Return on Equity at 5.60%, Operating Margin at 14.00%, Profit Margin at 8.57%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether EPS Growth improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at 5.60% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 10.90% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a moderate-to-high risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Mixed fundamentals with both positives (PEG Ratio, Institutional Own.) and negatives (EPS Growth, Return on Equity). A cautious approach is warranted. Monitor for improvement in weak areas before increasing conviction.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
ZBH Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
ZBH's Price-to-Sales ratio of 2.08x trades 38% below its historical average of 3.33x (3th percentile). The current valuation is 66% below its historical high of 6.07x set in Apr 2007, and 10% above its historical low of 1.89x in Feb 2009. Over the past 12 months, the PS ratio has compressed from ~2.4x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Zimmer Biomet Holdings Inc (ZBH) · HEALTHCARE › MEDICAL DEVICES
The Big Picture
Zimmer Biomet Holdings Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 8.2B with 11% growth year-over-year. Profit margins are thin at 8.6%, typical for companies in this phase that are reinvesting heavily in growth.
Key Findings
Generating 366M in free cash flow and 517M in operating cash flow. Earnings are translating into actual cash generation.
Earnings fell 41% YoY while revenue grew 11%. This gap usually reflects one-time items (tax benefits, write-offs) in the prior period, not an operational decline.
What to Watch Next
Margin expansion: can Zimmer Biomet Holdings Inc push profit margins above 15% as the business scales?
Debt management: total debt of 7.5B is significantly higher than cash (592M). Monitor refinancing risk.
Sector dynamics: monitor MEDICAL DEVICES industry trends, competitive moves, and regulatory changes that could impact Zimmer Biomet Holdings Inc.
Bottom Line
Zimmer Biomet Holdings Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions(109 last 3 months)
| Insider | Type | Shares |
|---|---|---|
WINKLER, LORI SVP and CHRO | Sell | -2,650 |
| Insider | Type | Shares |
|---|---|---|
YI, SANG Group President, Asia Pacific | Sell | -1,000 |
Data sourced from SEC Form 4 filings
Last updated: 12:56:57 PM
About Zimmer Biomet Holdings Inc(ZBH)
NYSE
HEALTHCARE
MEDICAL DEVICES
USA
Zimmer Biomet is a publicly traded medical device company. The company is headquartered in Warsaw, Indiana, where it is part of the medical devices business cluster.